CSL Production Process Caused Fluvax Problem, Firm's Probe Reveals
This article was originally published in PharmAsia News
Executive Summary
CSL's Fluvax influenza vaccine caused an excessive immune response in young children because of a fault in the Australian company's manufacturing process, according to a two-year internal investigation.